Table 2.
Patient and tumor characteristics
| Patients | N = 23 | 100 (%) |
|---|---|---|
| Age, years, median (range) | 68 (46–91) | - |
| Sex | ||
| Male | 13 | 56.5 |
| Female | 10 | 43.5 |
| RPA class | ||
| I | 3 | 13.0 |
| II | 20 | 87.0 |
| Primary tumor site | ||
| Lung | 10 | 43.5 |
| Breast | 4 | 17.4 |
| Gastrointestinal tract | 4 | 17.4 |
| Other | 5 | 21.7 |
| Previous therapy (Yes) | 8 | 34.8 |
| Whole brain radiation therapy | 4 | 17.4 |
| Local radiation therapy | 3 | 13.0 |
| SRT | 1 | 4.3 |
| Tumor | N = 27 | 100 (%) |
| Diameter, cm, median (range) | 2.6 (2.1–4.0) | - |
| GTV size, cc, median (range) | 8.1 (3.2–33.0) | - |
| PTV size, cc, median (range) | 11.9 (4.8–39.7) | - |
| Prescribed dose | ||
| 35 Gy/5 fraction | 19 | 70.4 |
| 40 Gy/8 fraction | 8 | 29.6 |
| GTV D99, Gy, median (range) | ||
| 35 Gy/5 fraction | 39.2 (36.8–40.3) | - |
| 40 Gy/8 fraction | 45.4 (44.1–47.4) | - |
| VMAT (Yes) | 23 | 85.2 |
RPA Recursive partitioning analysis, SRT stereotactic radiotherapy, GTV gross tumor volume, PTV planning target volume, VMAT volumetric-modulated arc therapy, GTV D99 dose that covers 99% of the GTV